OncoZenge
4.15
SEK
+3.75 %
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+3.75%
-59.79%
-31.86%
+18.4%
+34.3%
+18.57%
-60.1%
-
-66.09%
oncozenge.se/investerare
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ONCOZ
Daily low / high price
3.85 / 4.16
SEK
Market cap
48.61M SEK
Turnover
184.59K SEK
Volume
46K
Financial calendar
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Niclas Holmgren | 11.8 % | 11.8 % |
| Linc AB | 10.0 % | 10.0 % |
| Ozbek, Andreas | 8.4 % | 8.4 % |
| Östersjöstiftelsen | 4.9 % | 4.9 % |
| Avanza Pension | 4.8 % | 4.8 % |
| Kalle Holmgren | 3.4 % | 3.4 % |
| Nordnet Pensionsförsäkring AB | 3.2 % | 3.2 % |
| Kildal, Stian | 2.6 % | 2.6 % |
| Jimmy Olsson | 2.5 % | 2.5 % |
| Joacim Mansolahti Friberg | 2.0 % | 2.0 % |
ShowingAll content types
Redeye: OncoZenge Q3 2024 - Approaching lift-off
Redeye: Redeye Initiates Coverage of OncoZenge
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools